BRPI0607750A2 - composições de matéria, e farmacêutica, dna, vetor de expressão, célula hospedeira, e, uso de uma composição de matéria - Google Patents
composições de matéria, e farmacêutica, dna, vetor de expressão, célula hospedeira, e, uso de uma composição de matériaInfo
- Publication number
- BRPI0607750A2 BRPI0607750A2 BRPI0607750-1A BRPI0607750A BRPI0607750A2 BR PI0607750 A2 BRPI0607750 A2 BR PI0607750A2 BR PI0607750 A BRPI0607750 A BR PI0607750A BR PI0607750 A2 BRPI0607750 A2 BR PI0607750A2
- Authority
- BR
- Brazil
- Prior art keywords
- matter
- composition
- expression vector
- dna
- independently
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
Abstract
COMPOSIçõES DE MATéRIA, E FARMACêUTICA, DNA, VETOR DE EXPRESSãO, CéLULA HOSPEDEIRA, E, USO DE UMA COMPOSIçãO DE MATéRIA. A invenção refere-se a uma composição de matéria da fórmula (I) (X^ 1^)~ a~-(F^ 1^)~ d~-(X^ 2^)~ b~-(F^ 2^)~ e~-{X^ 3^)~ c~ e seus multímeros, em que F^ 1^e F^ 2^ são partes com extensão de meia-vida, e d e e são, cada um, independentemente, O ou 1, contanto que pelo menos um dentre d e e seja 1; X^ 1^, X^ 2^, e X^ 3^ são, cada um, independentemente, -(L)~ f~-P-(L)~ g~-, e f e g são, cada um, independentemente, O ou 1; P é um peptídeo de toxina não maior que 80 resíduos de aminoácidos em comprimento, compreendendo pelo menos duas ligações de dissulfeto intrapeptídeo; L é um ligante opcional; e a, b e c são, cada um, independentemente, O ou 1, contanto que pelo menos um dentre a, b e c seja 1. A ligação à parte de extensão de meia-vida aumenta a meia-vida in vivo do peptídeo de toxina, que de outra forma seria rapidamente degradado. Uma composição farmacêutica compreende a composição e um carreador farmaceuticamente aceitável. Também descritos são um DNA que codifica a composição de matéria da presente invenção, um vetor de expressão que compreende o DNA, e uma célula hospedeira compreendendo o vetor de expressão. Os métodos de tratamento de um distúrbio autoimune, tal como, mas não limitado a, esclerose múltipla, diabetes tipo 1, obesidade, psoríase, doença de intestino inflamatório, dermatite mediada por contato, artrite reumatóide, artrite psoriática, rejeição a transplante, doença de enxert-versus-hospedeiro, e lupus e de prevenção ou mitigação de reincidência de um sintoma de esclerose múltipla são também descritos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67434205P | 2005-04-22 | 2005-04-22 | |
US11/406,454 US7833979B2 (en) | 2005-04-22 | 2006-04-17 | Toxin peptide therapeutic agents |
PCT/US2006/015199 WO2006116156A2 (en) | 2005-04-22 | 2006-04-18 | Toxin peptides with extended blood halflife |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0607750A2 true BRPI0607750A2 (pt) | 2009-11-24 |
Family
ID=37894298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0607750-1A BRPI0607750A2 (pt) | 2005-04-22 | 2006-04-18 | composições de matéria, e farmacêutica, dna, vetor de expressão, célula hospedeira, e, uso de uma composição de matéria |
Country Status (16)
Country | Link |
---|---|
US (2) | US7833979B2 (pt) |
EP (1) | EP1896080A2 (pt) |
JP (2) | JP5087536B2 (pt) |
KR (2) | KR20100017942A (pt) |
AR (1) | AR053234A1 (pt) |
AU (1) | AU2006239928B8 (pt) |
BR (1) | BRPI0607750A2 (pt) |
CA (1) | CA2604999A1 (pt) |
CR (1) | CR9452A (pt) |
EA (1) | EA013470B1 (pt) |
IL (1) | IL186527A0 (pt) |
MX (1) | MX2007013031A (pt) |
NO (1) | NO20076013L (pt) |
NZ (1) | NZ562201A (pt) |
TW (1) | TW200716748A (pt) |
WO (1) | WO2006116156A2 (pt) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
GB0414272D0 (en) * | 2004-06-25 | 2004-07-28 | Cellpep Sa | OsK1 derivatives |
WO2008008873A2 (en) * | 2006-07-14 | 2008-01-17 | Georgia Tech Research Corporation | Clc channel ligand |
WO2008051383A2 (en) * | 2006-10-19 | 2008-05-02 | Amgen Inc. | Use of alcohol co-solvents to improve pegylation reaction yields |
US7825093B2 (en) * | 2006-10-25 | 2010-11-02 | Amgen Inc. | Methods of using OSK1 peptide analogs |
US20080260738A1 (en) * | 2007-04-18 | 2008-10-23 | Moore Margaret D | Single chain fc, methods of making and methods of treatment |
JP5249319B2 (ja) * | 2007-05-14 | 2013-07-31 | ウニヴェルシダ ナシオナル アウトノマ デ メヒコ | ヒトT−リンパ球カリウムチャンネル(Kv1.3亜型)を高い選択性で遮断し、ラットにおける生体内でのDTH−応答を減少させる二つのサソリペプチドVm23及びVm24 |
US20090252729A1 (en) * | 2007-05-14 | 2009-10-08 | Farrington Graham K | Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto |
CA2840407A1 (en) * | 2007-05-22 | 2008-12-18 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
US20090148904A1 (en) * | 2007-11-13 | 2009-06-11 | Mayfield Stephen P | Production of cytotoxic antibody-toxin fusion in eukaryotic algae |
US8716437B2 (en) * | 2007-12-07 | 2014-05-06 | Steven A. Goldstein | Identification of toxin ligands |
AU2009246142A1 (en) | 2008-05-15 | 2009-11-19 | Transmolecular, Inc. | Treatment of metastatic tumors |
MY151184A (en) * | 2008-07-23 | 2014-04-30 | Hanmi Science Co Ltd | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
EP2341942A1 (en) | 2008-09-19 | 2011-07-13 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
US20110171163A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of ziconotide peptides |
EP2340045B1 (en) | 2008-09-19 | 2017-04-12 | Nektar Therapeutics | Polymer conjugates of protegrin peptides |
US8252228B1 (en) * | 2008-10-13 | 2012-08-28 | Abbott Cardiovascular Systems Inc. | Methods for sterilizing carriers for treatment of a kidney |
US20120121591A1 (en) * | 2009-03-20 | 2012-05-17 | Amgen Inc. | SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3 |
EP2437767B1 (en) * | 2009-06-01 | 2015-07-08 | MedImmune, LLC | Molecules with extended half-lives and uses thereof |
CA2781532A1 (en) | 2009-11-20 | 2011-05-26 | Amgen Inc. | Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1 |
LT2531206T (lt) | 2010-02-04 | 2017-09-25 | Morphotek, Inc. | Chlorotoksino polipeptidai ir konjugatai ir jų naudojimas |
EP2569330B1 (en) * | 2010-05-11 | 2016-09-28 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
EA201370030A1 (ru) | 2010-08-10 | 2013-06-28 | Амген Инк. | Бифункциональный количественный анализ in vitro связывания мишени для обнаружения нейтрализующих антител к антителам-мишеням |
US8993727B2 (en) | 2010-09-22 | 2015-03-31 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
JP2014509859A (ja) | 2011-03-16 | 2014-04-24 | アムジエン・インコーポレーテツド | 17nav1.3およびnav1.7の強力かつ選択的阻害剤 |
EP2717899A4 (en) | 2011-06-06 | 2015-07-29 | Kineta One Llc | PHARMACEUTICAL COMPOSITIONS BASED ON SHK AND METHODS OF MAKING AND USING THE SAME |
IN2014CN03333A (pt) * | 2011-10-03 | 2015-07-03 | Univ California | |
WO2013061106A1 (en) * | 2011-10-28 | 2013-05-02 | University Of Debrecen | Modified peptide toxins |
JP6158090B2 (ja) * | 2011-10-31 | 2017-07-05 | ダニエル・ジェイ・カポン | 非ペプチドヒンジ部含有フレキシブル抗体様分子 |
JP2015509091A (ja) | 2012-01-09 | 2015-03-26 | ザ スクリプス リサーチ インスティテュート | ヒト化抗体 |
AU2013263349B2 (en) | 2012-05-17 | 2016-09-08 | Extend Biosciences, Inc | Carriers for improved drug delivery |
US10414808B2 (en) | 2012-05-18 | 2019-09-17 | Janssen Biotech, Inc. | Huwentoxin-IV variants and methods of use |
US9102751B2 (en) | 2012-05-18 | 2015-08-11 | Janssen Biotech, Inc. | Huwentoxin-IV variants and methods of use |
WO2014057687A1 (ja) | 2012-10-11 | 2014-04-17 | 第一三共株式会社 | 抗体-薬物コンジュゲート |
JP6272230B2 (ja) | 2012-10-19 | 2018-01-31 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体−薬物コンジュゲート |
AU2013359429A1 (en) | 2012-12-10 | 2015-07-09 | Fred Hutchinson Cancer Research Center | Methods for screening |
WO2014099984A1 (en) | 2012-12-20 | 2014-06-26 | Amgen Inc. | Apj receptor agonists and uses thereof |
JP6469590B2 (ja) | 2013-01-25 | 2019-02-13 | ヤンセン バイオテツク,インコーポレーテツド | Kv1.3アンタゴニスト及び使用方法 |
PL2956165T3 (pl) * | 2013-02-14 | 2020-04-30 | The Board Of Trustees Of The University Of Arkansas | Kompozycje i sposoby wzmacniania odpowiedzi immunologicznych na Eimeria lub ograniczania infekcji Eimeria |
US10344060B2 (en) | 2013-03-12 | 2019-07-09 | Amgen Inc. | Potent and selective inhibitors of Nav1.7 |
WO2014160037A2 (en) | 2013-03-14 | 2014-10-02 | The Regents Of The University Of California | Activatable membrane-interacting peptides and methods of use |
EP3022221B1 (en) | 2013-07-18 | 2021-09-15 | Taurus Biosciences, LLC | Humanized antibodies with ultralong complementarity determining regions |
JP2016527250A (ja) * | 2013-07-22 | 2016-09-08 | キネタ ワン リミテッド ライアビリティ カンパニーKineta One,Llc | 毒素系治療用ペプチド及びその医薬組成物の眼科的使用 |
US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
KR20160064192A (ko) | 2013-10-03 | 2016-06-07 | 얀센 바이오테크 인코포레이티드 | 프로톡신-ii 변이체 및 사용 방법 |
AU2013404615B2 (en) * | 2013-10-28 | 2018-05-17 | Baylor College Of Medicine | Novel scorpion toxin analogue and method for treating autoimmune diseases |
CA2933666C (en) * | 2013-12-25 | 2021-08-03 | Sapporo Medical University | Anti-trop2 antibody-drug conjugate |
KR102362920B1 (ko) | 2014-01-31 | 2022-02-14 | 다이이찌 산쿄 가부시키가이샤 | 항-her2 항체-약물 접합체 |
SG11201608309PA (en) | 2014-04-10 | 2016-11-29 | Daiichi Sankyo Co Ltd | Anti-her3 antibody-drug conjugate |
WO2015155976A1 (ja) | 2014-04-10 | 2015-10-15 | 第一三共株式会社 | 抗her2抗体-薬物コンジュゲート |
GB201408135D0 (en) * | 2014-05-08 | 2014-06-25 | Conogenetix Biosciences Gmbh | Kv1.3 potassium channel antagonists |
US10941182B2 (en) | 2014-06-10 | 2021-03-09 | Amgen Inc. | Apelin polypeptides |
CN104177489B (zh) * | 2014-07-29 | 2017-03-22 | 暨南大学 | 基因重组TNF‑α衍生物RMP16及其制备方法与应用 |
WO2016025129A1 (en) | 2014-08-14 | 2016-02-18 | Alhamadsheh Mamoun M | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
CA2958578A1 (en) | 2014-08-21 | 2016-02-25 | The General Hospital Corporation | Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
CA2964463C (en) | 2014-10-22 | 2024-02-13 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
EP3215172B1 (en) | 2014-11-07 | 2023-04-26 | Kineta Chronic Pain, Llc. | Modifications and uses of conotoxin peptides |
WO2016112208A2 (en) * | 2015-01-09 | 2016-07-14 | Kineta One, Llp | Topical applications of kv1.3 channel blocking peptides to treat skin inflammation |
MA41642A (fr) | 2015-03-03 | 2018-01-09 | Janssen Biotech Inc | Variants de protoxine ii et méthodes d'utilisation |
EP3277304B1 (en) | 2015-04-02 | 2021-08-04 | Janssen Biotech, Inc. | Protoxin-ii variants and methods of use |
EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
IL290959B2 (en) | 2015-06-29 | 2023-04-01 | Daiichi Sankyo Co Ltd | Preparations containing antibody-drug conjugates and methods for their production |
JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス,インク. | 単一ドメイン血清アルブミン結合タンパク質 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
KR102365977B1 (ko) | 2016-05-20 | 2022-02-22 | 하푼 테라퓨틱스, 인크. | 단일 쇄 가변 단편 cd3 결합 단백질 |
BR112019010602A2 (pt) | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | proteínas trispecíficas para psma e métodos de uso |
EP3544997A4 (en) | 2016-11-23 | 2020-07-01 | Harpoon Therapeutics, Inc. | PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN |
EP3496742A4 (en) * | 2016-12-01 | 2020-04-08 | University Of South Florida | PEPTICORPS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING EAR FIBRILLATION |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
CN110049779A (zh) | 2016-12-12 | 2019-07-23 | 第一三共株式会社 | 抗体-药物缀合物和免疫检查点抑制剂的组合 |
CA3050668C (en) | 2017-01-17 | 2023-08-15 | Daiichi Sankyo Company, Limited | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
US10668113B2 (en) | 2017-03-31 | 2020-06-02 | Vivekananda Ramana | Formulation for targeting cancer in humans and canines using venom |
US10668130B2 (en) | 2017-03-31 | 2020-06-02 | Vivekananda Ramana | Formulation for targeting cancer in humans and canines using chlorotoxin |
US10668112B2 (en) | 2017-03-31 | 2020-06-02 | Vivekananda Ramana | Formulation for targeting cancer in humans and canines |
EP3621648A4 (en) | 2017-05-12 | 2021-01-20 | Harpoon Therapeutics, Inc. | TRISPECIFIC PROTEINS MSLN AND METHOD OF USE |
JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス,インク. | メソテリン結合タンパク質 |
TW202330036A (zh) | 2017-05-15 | 2023-08-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
GB201711208D0 (en) | 2017-07-12 | 2017-08-23 | Iontas Ltd | Ion channel inhibitors |
WO2019012015A1 (en) * | 2017-07-12 | 2019-01-17 | Iontas Limited | POTASIC CHANNEL INHIBITORS |
IL272964B2 (en) | 2017-08-31 | 2024-02-01 | Daiichi Sankyo Co Ltd | Production method for antibody-drug conjugates |
KR20200041993A (ko) | 2017-08-31 | 2020-04-22 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 개량 제조 방법 |
WO2019074858A1 (en) * | 2017-10-09 | 2019-04-18 | Blaze Bioscience, Inc. | PEPTIDES BINDING TO IONIC CHANNELS AND METHODS OF USE |
AU2018346955A1 (en) | 2017-10-13 | 2020-04-30 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
CN111630070A (zh) | 2017-10-13 | 2020-09-04 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
RS64379B1 (sr) | 2018-05-18 | 2023-08-31 | Glycotope Gmbh | Anti-muc1 antitelo |
JP7300186B2 (ja) * | 2018-05-24 | 2023-06-29 | 国立大学法人 熊本大学 | 薬物送達用担体 |
JP7425049B2 (ja) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | Dll3結合タンパク質および使用方法 |
MX2022003300A (es) | 2019-09-20 | 2022-07-13 | Zealand Pharma As | Bloqueadores kv1.3. |
JP2023527609A (ja) | 2020-02-21 | 2023-06-30 | ハープーン セラピューティクス,インク. | Flt3結合タンパク質および使用方法 |
WO2022066767A2 (en) | 2020-09-23 | 2022-03-31 | Aldevron, Llc | Potent and selective inhibitors of nav1.7 |
CN112353934B (zh) * | 2020-11-23 | 2023-05-19 | 中国人民解放军军事科学院军事医学研究院 | 一种芋螺毒素药物组合物及其冻干制剂 |
WO2022200374A1 (en) | 2021-03-23 | 2022-09-29 | Zealand Pharma A/S | Kv1.3 blockers |
WO2024083919A1 (en) | 2022-10-18 | 2024-04-25 | Zealand Pharma A/S | Inhibitors |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
JPH0669959B2 (ja) | 1985-09-26 | 1994-09-07 | 東燃株式会社 | コレラ毒素類を活性成分とする免疫抑制剤 |
AU607172B2 (en) | 1986-12-22 | 1991-02-28 | Cygnus, Inc. | Diffusion matrix for transdermal drug administration |
US5023084A (en) | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
EP0303681B1 (en) | 1987-02-24 | 1992-10-14 | Xoma Corporation | Immunosuppression in immunotoxin based human therapy |
US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US4925677A (en) | 1988-08-31 | 1990-05-15 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
US4994439A (en) | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
US5397702A (en) | 1989-03-06 | 1995-03-14 | The Regents Of The University Of California | Assay for and treatment of autoimmune diseases |
US4994436A (en) * | 1989-03-10 | 1991-02-19 | American Air Liquide | Process for safely destroying organic binders in ceramic components during the firing process |
US4906159A (en) | 1989-03-22 | 1990-03-06 | Caterpillar Industrial Inc. | Freely positionable load carrying attachment for an automatic guided vehicle |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
US5171264A (en) | 1990-02-28 | 1992-12-15 | Massachusetts Institute Of Technology | Immobilized polyethylene oxide star molecules for bioapplications |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
IL98932A0 (en) | 1990-07-27 | 1992-07-15 | Univ California | Assay,kits and methods based on nk+channel expression |
JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
SG89295A1 (en) | 1991-03-15 | 2002-06-18 | Amgen Inc | Pegylation of polypeptides |
CA2082951C (en) | 1991-03-15 | 1999-12-21 | Robert M. Platz | Pulmonary administration of granulocyte colony stimulating factor |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
JPH0640945A (ja) | 1992-07-23 | 1994-02-15 | Kureha Chem Ind Co Ltd | Fcフラグメント結合抗腫瘍剤 |
US5346701A (en) | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
US5494895A (en) | 1993-07-22 | 1996-02-27 | Merck & Co., Inc. | Scorpion peptide margatoxin with immunosuppressant activity |
US5460820B1 (en) | 1993-08-03 | 1999-08-03 | Theratech Inc | Method for providing testosterone and optionally estrogen replacement therapy to women |
US6342225B1 (en) | 1993-08-13 | 2002-01-29 | Deutshces Wollforschungsinstitut | Pharmaceutical active conjugates |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
AU1843295A (en) | 1994-02-23 | 1995-09-11 | Chiron Corporation | Method and compositions for increasing the serum half-life of pharmacologically active agents |
FR2717688B1 (fr) | 1994-03-28 | 1996-07-05 | Lhd Lab Hygiene Dietetique | Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA. |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
CZ288146B6 (en) | 1994-12-22 | 2001-05-16 | Astra Ab | Pharmaceutical aerosol preparation, process of its preparation and use |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US5783208A (en) | 1996-07-19 | 1998-07-21 | Theratech, Inc. | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
US5763478A (en) | 1996-10-16 | 1998-06-09 | Merck & Co., Inc. | Triterpene derivatives with immunosuppressant activity |
WO1998023639A2 (en) | 1996-11-27 | 1998-06-04 | University Of Florida | ShK TOXIN COMPOSITIONS AND METHODS OF USE |
EP0916681B1 (en) | 1996-12-26 | 2005-10-26 | Suntory Limited | Neuropeptides originating in scorpion |
US6548644B1 (en) | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
SG129211A1 (en) | 1997-11-06 | 2007-02-26 | Univ Singapore | Therapeutic molecules |
US6703485B2 (en) | 1997-12-23 | 2004-03-09 | The Trustees Of Columbia University In The City Of New York | Brain and heart cyclic nucleotide gated ion channel compounds and uses thereof |
US6551821B1 (en) | 1997-12-23 | 2003-04-22 | The Trustees Of Columbia University In The City Of New York | Brain cyclic nucleotide gated ion channel and uses thereof |
CA2316755C (en) | 1998-01-23 | 2006-04-04 | Prolifaron, Inc. | Methods and compositions for the identification of growth factor mimetics, growth factors and inhibitors |
JP3530004B2 (ja) | 1998-02-06 | 2004-05-24 | 株式会社日立ユニシアオートモティブ | 吸入式投薬器 |
US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
US6166322A (en) * | 1999-04-16 | 2000-12-26 | Industrial Technology Research Institute | Encapulation process for mono-and polycrystalline silicon solar cell modules |
US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
EP1105409B1 (en) | 1999-05-17 | 2006-03-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
EP1185654A2 (en) | 1999-06-22 | 2002-03-13 | E.I. Du Pont De Nemours And Company | Scorpion toxins from buthotus judaicus |
US6768002B1 (en) | 1999-06-22 | 2004-07-27 | E. I. Du Pont De Nemours And Company | Scorpion toxins |
US6096891A (en) | 1999-12-09 | 2000-08-01 | Air Products And Chemicals, Inc. | Process for the production of cyclic N,N'-dialkylureas |
WO2001062827A2 (en) | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
SE0000935D0 (sv) | 2000-03-21 | 2000-03-21 | Astrazeneca Ab | An inhalation device |
JP2003530838A (ja) | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CA2407956A1 (en) | 2000-05-03 | 2001-11-08 | Amgen Inc. | Modified peptides as therapeutic agents |
EP1177806A1 (en) | 2000-08-04 | 2002-02-06 | The Technology Partnership Public Limited Company | Dry powder inhaler |
US7189830B2 (en) * | 2001-02-19 | 2007-03-13 | Merck Patent Gmbh | Anti-KSA/IL-2 fusion proteins with reduced immunogenicity |
JP4336771B2 (ja) | 2001-03-09 | 2009-09-30 | モルフォシス アーゲー | 血清アルブミン結合部分 |
US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6861405B2 (en) | 2001-06-12 | 2005-03-01 | Yale University | Compositions and methods relating to glucose metabolism, weight control, and food intake |
US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
CA2484556A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US6900317B2 (en) | 2002-02-19 | 2005-05-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them |
TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
GB0219512D0 (en) | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Inhalation compositions with high drug ratios |
US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
WO2004043396A2 (en) | 2002-11-09 | 2004-05-27 | Nobex Corporation | Modified carbamate-containing prodrugs and methods of synthesizing same |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
DK1641483T3 (da) | 2003-06-12 | 2008-06-02 | Lilly Co Eli | Fusionsproteiner |
AU2004282984B2 (en) | 2003-11-13 | 2011-07-14 | Hanmi Science Co., Ltd. | Protein complex using immunoglobulin fragment andmethod for the preparation thereof |
GB0414272D0 (en) | 2004-06-25 | 2004-07-28 | Cellpep Sa | OsK1 derivatives |
ES2629397T3 (es) | 2004-09-24 | 2017-08-09 | Amgen Inc. | Moléculas de Fc modificadas |
JP5118969B2 (ja) | 2004-10-07 | 2013-01-16 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア | Kv1.3カリウムチャネルの選択的阻害におけるShKトキシンの類似体ならびにその使用方法 |
US7825093B2 (en) | 2006-10-25 | 2010-11-02 | Amgen Inc. | Methods of using OSK1 peptide analogs |
US20120121591A1 (en) | 2009-03-20 | 2012-05-17 | Amgen Inc. | SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3 |
-
2006
- 2006-04-17 US US11/406,454 patent/US7833979B2/en active Active
- 2006-04-18 NZ NZ562201A patent/NZ562201A/en not_active IP Right Cessation
- 2006-04-18 KR KR1020097027223A patent/KR20100017942A/ko not_active Application Discontinuation
- 2006-04-18 KR KR1020077027146A patent/KR20080021606A/ko active Search and Examination
- 2006-04-18 WO PCT/US2006/015199 patent/WO2006116156A2/en active Search and Examination
- 2006-04-18 MX MX2007013031A patent/MX2007013031A/es active IP Right Grant
- 2006-04-18 EP EP06751051A patent/EP1896080A2/en not_active Withdrawn
- 2006-04-18 BR BRPI0607750-1A patent/BRPI0607750A2/pt not_active IP Right Cessation
- 2006-04-18 AU AU2006239928A patent/AU2006239928B8/en not_active Ceased
- 2006-04-18 CA CA002604999A patent/CA2604999A1/en not_active Abandoned
- 2006-04-18 JP JP2008507949A patent/JP5087536B2/ja not_active Expired - Fee Related
- 2006-04-18 EA EA200702313A patent/EA013470B1/ru not_active IP Right Cessation
- 2006-04-21 AR ARP060101572A patent/AR053234A1/es not_active Application Discontinuation
- 2006-04-24 TW TW095114588A patent/TW200716748A/zh unknown
-
2007
- 2007-10-09 IL IL186527A patent/IL186527A0/en unknown
- 2007-10-19 CR CR9452A patent/CR9452A/es not_active Application Discontinuation
- 2007-11-21 NO NO20076013A patent/NO20076013L/no not_active Application Discontinuation
-
2010
- 2010-11-02 US US12/938,294 patent/US8907071B2/en active Active
-
2011
- 2011-12-19 JP JP2011276723A patent/JP5220915B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EA200702313A1 (ru) | 2008-06-30 |
MX2007013031A (es) | 2007-12-12 |
CA2604999A1 (en) | 2006-11-02 |
US8907071B2 (en) | 2014-12-09 |
AR053234A1 (es) | 2007-04-25 |
US7833979B2 (en) | 2010-11-16 |
AU2006239928B8 (en) | 2011-03-31 |
NO20076013L (no) | 2008-01-22 |
WO2006116156A3 (en) | 2007-10-04 |
WO2006116156A2 (en) | 2006-11-02 |
KR20100017942A (ko) | 2010-02-16 |
JP2012100671A (ja) | 2012-05-31 |
AU2006239928B2 (en) | 2010-12-02 |
NZ562201A (en) | 2011-03-31 |
KR20080021606A (ko) | 2008-03-07 |
EP1896080A2 (en) | 2008-03-12 |
CR9452A (es) | 2008-05-21 |
JP2008538506A (ja) | 2008-10-30 |
EA013470B1 (ru) | 2010-04-30 |
TW200716748A (en) | 2007-05-01 |
JP5087536B2 (ja) | 2012-12-05 |
JP5220915B2 (ja) | 2013-06-26 |
US20070071764A1 (en) | 2007-03-29 |
IL186527A0 (en) | 2008-01-20 |
US20110045587A1 (en) | 2011-02-24 |
AU2006239928A1 (en) | 2006-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0607750A2 (pt) | composições de matéria, e farmacêutica, dna, vetor de expressão, célula hospedeira, e, uso de uma composição de matéria | |
TW200833840A (en) | Toxin peptide therapeutic agents | |
DK1765860T3 (da) | Ny-ESO-T.cellereceptor med höj affinitet | |
CY1116285T1 (el) | Ανασυνδυασμενες ν-γλυκοζυλιωμενες πρωτεϊνες απο προκαρυωτικα κυτταρα | |
WO2007076200A3 (en) | Antagonists of hmgb1 and/or rage and methods of use thereof | |
WO2009023270A3 (en) | Compositions and methods for modifying properties of biologically active polypeptides | |
WO2011075393A3 (en) | Glucagon/glp-1 receptor co-agonists | |
RU2014122609A (ru) | Модифицированная константная область антитела | |
NZ628987A (en) | Extended recombinant polypeptides and compositions comprising same | |
TNSN08064A1 (en) | Albumin fusion proteins | |
BRPI0511429A (pt) | proteìna de ligação à fibronectina (fnb) isolada, alterada de staphylococcal aureus (s. aureus); fnb isolada, alterada; composição imunogênica; método para imunizar um vertebrado contra s. aureus; vetor de expressão; célula hospedeira recombinante; método para produzir uma fnb alterada; método para induzir uma resposta imunológica em um vertebrado; proteìna isolada, alterada de ligação à fibronectina (fnb) de staphylococcal aureus (s. aureus); e molécula isolada de ácido nucléico que codifica uma fnb alterada de s. aureus | |
MX336623B (es) | Peptidos penetradores de las celulas y usos de los mismos. | |
MX356675B (es) | Polipeptidos interleuquina- 2 mutantes. | |
TR201900128T4 (tr) | Amino asit 1'de ve 3'te modifiye edilmiş siklosporin analoğu moleküller. | |
BRPI0716088B8 (pt) | anticorpo isolado, composição, molécula de ácido nucléico isolada, vetor, método para produzir um anticorpo, hibridoma, e, kit | |
UA96308C2 (ru) | Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение | |
WO2006105021A3 (en) | Gitr binding molecules and uses therefor | |
EA033437B9 (ru) | Fc-гамма-рецептор iib и его применение для лечения или предупреждения воспалительных и/или аутоиммунных заболеваний | |
WO2008129971A1 (ja) | 改良された持続感染型センダイウイルスベクター | |
CL2007002958A1 (es) | Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr | |
MX2009012272A (es) | Vectores para la expresion de genes multiples. | |
WO2008103378A3 (en) | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist | |
DE60135850D1 (de) | Urocortinproteine und deren verwendungen | |
UA94226C2 (ru) | Пептидные токсины как терапевтические средства | |
WO2009079566A3 (en) | Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/60 (2017.01), C07K 14/435 (2006.01), A61K |